Annual HVTN Translational HIV Early Stage Investigator (ESI) Conference

年度 HVTN 转化 HIV 早期研究者 (ESI) 会议

• 批准号: 10376029
• 负责人: James G. Kublin
• 金额: $ 7.5万
• 依托单位: FRED HUTCHINSON CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-04-07 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10376029
• 关键词: AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Address; Affect; Animal Model; Award; Career Choice; Childhood; Clinical Research; Clinical Trials; Clinical Trials Design; Collaborations; Communicable Diseases; Development; Disabled Persons; Disease; Disease remission; Epidemic; Evaluation; Event; Funding; Grant; Group Meetings; HIV; HIV Vaccine Trials Network; HIV vaccine; HIV/TB; Human; Individual; Infection; International; Intervention; Knowledge; Learning; Mentors; Modeling; Monoclonal Antibodies; Needs Assessment; Peer Review; Prevention; Prevention strategy; Primates; Process; Randomized; Reproducibility; Request for Applications; Research; Research Personnel; Resources; Role; Science; Scientist; Secure; Talents; Therapeutic; Time; Training; Training Programs; Translating; Translational Research; Translations; Travel; Tuberculosis; Tuberculosis Vaccines; Underrepresented Minority; United States National Institutes of Health; Vaccines; Viral; Vision; Woman; Work; Workforce Development; Writing; antiretroviral therapy; base; career; career development; career networking; co-infection; comorbidity; cost; efficacy trial; experimental study; innovation; meetings; multidisciplinary; nonhuman primate; novel; pandemic disease; peer; phase III trial; pre-clinical; preclinical study; prevent; programs; skill acquisition; skills; success; symposium; vaccine evaluation; vaccine-induced antibodies

PROJECT SUMMARY ANNUAL HVTN TRANSLATIONAL HIV EARLY STAGE INVESTIGATOR (ESI) CONFERENCE This R13 application requests continued NIH support for four annual conferences for Early Stage Investigators (ESIs) conducting translational HIV vaccine, co-morbidity, barrier to infection, and cure research with nonhuman primates (NHPs). The Conference offers an intimate setting where ESIs build skills, knowledge, professional networks and career development strategies with their peers and senior investigators in the field. Year 1 is proposed to take place September 28-29, 2020 in Portland, OR, immediately preceding the 38th NHP-AIDS Symposium, with complementary programming planned. Subsequent meetings will be adjacent to either the Symposium or HIV Vaccine Trials Network (HVTN) Full Group Meeting, allowing for additional opportunities for learning, training and networking. Conference topic selection will be guided by a needs assessment from K01 HIV/AIDS Scholars and mentors, an innovative practice used to great effect for the 2017-2019 Conferences. Agenda development and advising for these Conferences will be led by a diverse, multi-disciplinary group of experts in the fields at multiple stages in their careers. Attendees at the ESI Conferences will participate in training and skill-building activities on important translational scientific topics (e.g., state of prevention, vaccine, therapeutic and cure research; TB and coinfections in the NHP model); mentoring opportunities with senior and peer investigators (e.g., panel discussions on partnerships and career paths in the field); career development training (e.g., ESI funding landscape, how to conduct research with HVTN); “Works in Progress” presentations; and organized networking opportunities with other ESIs and senior investigators (e.g., receptions, randomized seating). We will fund attendance at these Conferences and the HVTN Full Group Meeting or NHP-AIDS Symposium for talented ESIs, with priority for underrepresented applicants, and K01 mentors, providing opportunities for these groups to continue to interact and support translational science. The Conference is open to all qualified investigators at no cost to attendees. Inclusion of women, underrepresented minorities and individuals with disabilities will be supported as speakers, attendees and advisors. The Conferences will be organized by staff at the HVTN, the world’s largest publicly funded collaboration facilitating the development and testing of vaccines to prevent HIV/AIDS. They will be housed within the existing HVTN Training Program, which has shown considerable success in supporting investigators at multiple career stages, and which organized highly meaningful and impactful ESI Conferences from 2017-2019. These conferences fill a critical gap in scientific knowledge and workforce development by facilitating greater translation of research between preclinical NHP studies and clinical trials, which will ultimately accelerate progress towards controlling the HIV epidemic and related co-infections in the coming decade.

项目摘要 年度HVTN转化HIV早期研究员（ESI）会议 R13申请要求继续为早期调查人员提供四次年度会议的NIH支持 （ESI）进行转化HIV疫苗，合并症，感染障碍以及治愈非人类的研究 素数（NHP）。会议提供了一个私密的环境，ESIS建立技能，知识，专业 网络和职业发展策略与该领域的同龄人和高级调查员。 1年是 提议于2020年9月28日至29日在波特兰举行，或在第38届NHP-AIDS之前举行 研讨会，计划完整的编程。随后的会议将与 专题讨论会或HIV疫苗试验网络（HVTN）完整小组会议，为其他机会提供更多机会 学习，培训和网络。会议主题选择将以K01的需求评估为指导 艾滋病毒/艾滋病学者和导师，这是一种创新的实践，用于2017-2019会议。 这些会议的议程发展和咨询将由潜水员的多学科小组领导 该领域的专家在职业生涯的多个阶段。 ESI会议的与会者将参加 有关重要翻译科学主题的培训和技能建设活动（例如，预防状态，疫苗， 治疗和治疗研究； NHP模型中的结核和共感染）；与高级和 同行调查人员（例如，关于该领域的伙伴关系和职业道路的小组讨论）；职业发展 培训（例如，ESI资金景观，如何使用HVTN进行研究）； “正在进行的”演示； 并与其他ESI和高级研究人员（例如接待，随机分组）有组织的网络机会 座位）。我们将资助参加这些会议和HVTN完整小组会议或NHP-AIDS 天才ESI的研讨会，对代表性不足的申请人和K01导师的优先级 这些群体继续互动和支持转化科学的机会。会议开放 给所有合格的调查人员，免费给与会者。包括妇女，代表性不足的少数民族和 残疾人将作为演讲者，与会者和顾问支持。会议将是 由HVTN的员工组织，全球最大的公共资助合作促进了发展和 测试疫苗以防止艾滋病毒/艾滋病。他们将安置在现有的HVTN培训计划中，该计划 在多个职业阶段支持调查人员方面表现出了很大的成功，并且有组织 从2017 - 2019年开始，高度意义和有影响力的ESI会议。这些会议填补了关键的空白 科学知识和劳动力发展通过促进临床前研究的更大翻译 NHP研究和临床试验，最终将加速控制HIV流行 和相关的共同感染在未来十年中。